Launch of the Early Assets Program

There is a clear gap between the immense “market” opportunity represented by brain and sensory diseases, the immense medical and social need to be able to live and age with good brain health and... the level of investment that is still too low by investors.

The main reason so far has obviously been the risk The failure of new products in these sectors is largely due to the complexity of the brain in general, but also to the diversity of brains that makes it less easy to predict the effectiveness of interventions.

The Brain&Mind biocluster will deploy 100 million Euros to change this situation, with a series of investment levers to improve the competitiveness of this R&D sector. The considerable scientific advances of the last few years now allow it.

The first “Tool” deployed by Brain&Mind is therefore the De-risking health technologies driven by innovative startups. After meeting with dozens of companies in the early stages of development, as well as dozens of investment funds, we believe we have found the right mechanism to restore trust: Strengthen the initial data package, prepare for the first clinical validation, integrate startups into excellent clinical networks.

The first startups selected

After an in-depth analysis of the SCIENCE supporting the projects, Brain&Mind selected the following startups:

· APERTUM : Specializing in the use of transcranial magnetic stimulation (TMS) to improve the effectiveness of low-dose drugs, this company aims to redefine the therapeutic potential of TMS.

· CLARITY : Developing a 40 Hz neuromodulation protocol, CLARITY is positioned as a key player in the treatment of neurodegenerative diseases, with a solution that could complement existing treatments for Alzheimer's disease.

· E-TONUS : This startup has designed an innovative device that uses peripheral nerve stimulation to access brain pain circuits, offering new perspectives for the management of chronic pain.

· KWIT : Promoted by the WHO, KWIT is making a major transition from its wellness mobile application to a medical device, thus supporting users in their smoking cessation journey.

· LUTECE DYNAMICS : Coming from the laboratories of the Institut de la Vision, LUTECE is revolutionizing cellular imaging with technologies to explore the subcellular dynamics of organelles, a major advance for neuroscience research.

· ORIA : Specializing in microfluidics, ORIA explores the electrophysiology of organelles, in particular lysosomes and mitochondria, offering promising perspectives for research on neurodegenerative diseases.

Technological development programs will begin as early as July this year, accompanied by scientific and medical experts from the Brain&Mind community. They are financially supported by the Ile de France Region and by the France 2030 plan.

About Brain&Mind

Created as part of France 2030 plan, the biocluster Brain&Mind brings together the best scientific, medical and technological expertise in the fields of neurology, psychiatry and sensory disabilities.

The project is distinguished by the integration of leading industrial players and by its focus on “after-lab”, i.e. the development of new health products. It addresses preventive approaches as well as biotherapies and neurotechnologies. It benefits from an initial support of 100 million Euros to develop an innovation community that is as open as possible and to invest in disruptive technologies.

Press contact
Lerebourg Ambre
Communication and marketing manager
ambre.lerebourg@brainandmind.fr